Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 3/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | MITF | O75030 | 1/20 | 0.50 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.49 |
| ▸ | DBH | P09172 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 2/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | CA2 | P00918 | 1/20 | 0.45 |
| ▸ | TUBB1 | Q9H4B7 | 1/20 | 0.44 |
| ▸ | KDM1A | O60341 | 1/20 | 0.44 |
| ▸ | MAOA | P21397 | 1/20 | 0.44 |
| ▸ | MAOB | P27338 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29442867 | 1.00 | HTT (0.50) | HTTALDH1A1KDM4EMITFCYP17A1 | |
| SCHEMBL2656831 | 0.85 | KDM4E (0.50) | HTTALDH1A1KDM4EMITFCYP17A1 | |
| SCHEMBL3162853 | 0.84 | CA2 (0.45) | ALDH1A1KDM4ESMN1; SMN2LMNAMAPK1 | |
| SCHEMBL8327653 | 0.82 | ALDH1A1 (0.59) | HTTALDH1A1KDM4EMITF | |
| SCHEMBL2759522 | 0.82 | HTT (0.51) | HTTALDH1A1KDM4EMITFCYP17A1 | |
| SCHEMBL29559892 | 0.81 | CA2 (0.68) | ALDH1A1KDM4ECA2 | |
| SCHEMBL1080853 | 0.81 | CA2 (0.68) | ALDH1A1KDM4ECA2 | |
| SCHEMBL8324389 | 0.81 | HTR7 (0.58) | HTTALDH1A1KDM4EMITFCYP17A1 | |
| SCHEMBL7766144 | 0.80 | KDM4E (0.46) | HTTALDH1A1KDM4EMITFCYP17A1 | |
| Ammonia Solution, Strong SCHEMBL23291273 | 0.80 | HTT (0.50) | HTTALDH1A1KDM4EMITFCYP17A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 285 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116640106-B | Phenylpiperazine compound and preparation method and application thereof | 郑州大学 | 2024-03-08 | — | — | CN | claimed |
| CN-116640106-A | Phenylpiperazine compound and preparation method and application thereof | 郑州大学 | 2023-08-25 | — | — | CN | claimed |
| US-12594292-B2 | Antiviral prodrugs, intermediate-and long-acting formulations and methods | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2026-04-07 | — | — | US | disclosed |
| US-12336991-B2 | Factor XIIA inhibitors | UNIVERSITY OF LEEDS (GB) | 2025-06-24 | — | — | US | disclosed |
| US-20250177428-A1 | ANTIVIRAL PRODRUGS, INTERMEDIATE-AND LONG-ACTING FORMULATIONS AND METHODS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2025-06-05 | — | — | US | disclosed |
| CN-119977833-A | Synthesis and antitumor application of erianin derivative | 江苏海洋大学 | 2025-05-13 | — | — | CN | disclosed |
| WO-2025072637-A1 | OXYGENATED HETEROCYCLIC LSD-1 INHIBITORS AND RELATED METHODS OF USE | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2025-04-03 | — | — | WO | disclosed |
| CN-119504726-A | BRD4 inhibitor and preparation method and application thereof | 四川大学华西医院 | 2025-02-25 | — | — | CN | disclosed |
| US-20250011358-A1 | ANTIVIRAL PRODRUGS, PHARMACEUTICAL FORMULATIONS, AND METHODS | UNIV CALIFORNIA (US) | 2025-01-09 | — | — | US | disclosed |
| US-20250011289-A1 | 1H-BENZO[B]AZEPIN-2(3H)-ONE COMPOUNDS, COMPOSITIONS AND METHODS OF TREATING CANCER | J. MICHAEL BISHOP INSTITUTE OF CANCER RESEARCH (CN) | 2025-01-09 | — | — | US | disclosed |
| US-12180221-B2 | Compounds and uses thereof | JANSSEN PHARMACEUTICA NV (BE) | 2024-12-31 | — | — | US | disclosed |
| WO-2005040169-A2 | FUSED HETEROCYCLIC COMPOUNDS AS SEROTONIN RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2005-05-06 | — | — | WO | disclosed |
| US-20050009840-A1 | 2-amino- pyridines and pyrazines additionally substituted witn one or more carbocyclic or heterocyclic groups, e.g., 4-[6-amino-5-(2,6-dichloro-benzyloxy)-pyridin-3-yl]-phenol, for treating many kinds of cancer | SUGEN, INC. | 2005-01-13 | — | — | US | disclosed |
| WO-2004076412-A2 | AMINOHETEROARYL COMPOUNDS AS PROTEIN KINASE INHIBITORS | SUGEN, INC. (US) | 2004-09-10 | — | — | WO | disclosed |
| US-6582351-B1 | Benzimidazole heterocyclic compounds having pharmacological activities, and their use as a medicament for treatment or prevention of diseases mediated by cGMP-PDE | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2003-06-24 | — | — | US | disclosed |
| CN-1374952-A | Benzimidazolone derivatives and their use as phosphodiesterase inhibibors | FUJISAWA PHARMACEUTICAL CO (JP) | 2002-10-16 | — | — | CN | disclosed |
| EP-1196391-A1 | BENZIMIDAZOLONE DERIVATIVES AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2002-04-17 | — | — | EP | disclosed |
| WO-2001005770-A1 | BENZIMIDAZOLONE DERIVATIVES AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2001-01-25 | — | — | WO | disclosed |
| US-4199595-A | M-phenoxybenzyl and α-cyano-M-phenoxybenzyl esters of 2-haloalkyl (oxy-, thio-, sulfinyl-, or sulfonyl)phenylalkanoic acids | AMERICAN CYANAMID COMPANY (US) | 1980-04-22 | — | — | US | disclosed |
| US-4178460-A | INTERMEDIATES FOR INSECTICIDES | AMERICAN CYANAMID CO. (US) | 1979-12-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12594292-B2 | Antiviral prodrugs, intermediate-and long-acting formulations and methods | ACE2, SARS1, FURIN | HTT 2014/4885ALDH1A1 4279/4885KDM4E 2683/4885 |
| US-20250011289-A1 | 1H-BENZO[B]AZEPIN-2(3H)-ONE COMPOUNDS, COMPOSITIONS AND METHODS OF TREATING CANCER | BRCA1, TP53, BCCIP | HTT 3529/4885ALDH1A1 729/4885KDM4E 235/4885 |
| US-12180221-B2 | Compounds and uses thereof | NLN, ACHE, CLN6 | HTT 6/4885ALDH1A1 656/4885KDM4E 2853/4885 |
| US-20050009840-A1 | 2-amino- pyridines and pyrazines additionally substituted witn one or more carbocyclic or heterocyclic groups, e.g., 4-[6-amino-5-(2,6-dichloro-benzyloxy)-pyridin-3-yl]-phenol, for treating many kinds of cancer | MET, ERBB2, CDK4 | HTT 4453/4885ALDH1A1 1269/4885KDM4E 298/4885 |
| US-20250177428-A1 | ANTIVIRAL PRODRUGS, INTERMEDIATE-AND LONG-ACTING FORMULATIONS AND METHODS | SARS1, ACE2, FURIN | HTT 2016/4885ALDH1A1 3768/4885KDM4E 4323/4885 |
| US-12336991-B2 | Factor XIIA inhibitors | F11, F13B, F12 | HTT 3216/4885ALDH1A1 2363/4885KDM4E 722/4885 |
| US-20250011358-A1 | ANTIVIRAL PRODRUGS, PHARMACEUTICAL FORMULATIONS, AND METHODS | MTAP, SARS1, RNGTT | HTT 1997/4885ALDH1A1 2865/4885KDM4E 2042/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.